The repair of old, damaged, or diseased tissues using gene or cell therapies promises a future where people live longer, healthier lives and Ireland is well placed to become a manufacturing hub for products based on this technology.
Gene therapy is the technology used to correct a gene defect that is causing an inherited genetic disease. Cell therapy is the use of living cells from the patient or a donor, to repair tissue or treat an inflammatory condition or disease. These therapies can be used alone or combined for greater effect.
Weve been interested, for a very long time in the development of new treatments for patients involving cell and gene therapy, says professor of cellular therapy at NUI Galway Frank Barry a co-founder of the Regenerative Medicine Institute (Remedi) in 2004.
Over the last several decades there have been some extraordinary, transformative developments in medicine; for example, antibiotics and monoclonal antibodies and these have had a dramatic impact on how diseases were treated, says Barry. Many people believe that cell and gene therapy represent the next transformative innovation that will change medicine.
There are many examples of outstanding success stories, where diseases which were previously untreatable are now actually being treated and were very anxious to continue to play a role in this, says Barry.
The combination of cell and gene therapy has been successful in treating cancers that were thought incurable. For example, stem cells have been taken from the blood of patients with specific cancers, genetically modified so they target a particular cancer, and are delivered back into the patients blood.
Gene therapy has had a troubled history with some adverse outcomes reported from early clinical trials two decades ago. Most notably, and tragically, was the case of 18-year-old Jesse Gelsinger, who died in 1999 during a University of Pennsylvania run gene therapy trial. Jesse suffered from a genetic disease affecting his liver which meant that he was unable to metabolise ammonia.
The learnings from that have proven to be very helpful not to diminish the impact of his death on his family and the tragedy of that, says Prof Tim OBrien, head of medicine at NUI Galway, an Irish pioneer of this field.
In Ireland, the origins of cell and gene therapy research go back to 2004, when Remedi was set up with funding from Science Foundation Ireland (SFI). Then in 2014, the Centre for Cell Manufacturing in Ireland (CCMI) was established. Barry and OBrien have been the key figures driving the process.
From the beginning, the dream of Barry and OBrien was to convert promising gene and cell therapy research into new therapies that could then be tested in clinical trials. Galway was a good place to do it, as it was known as a leading hub for medical device research and manufacturing, and it had the laboratories, hospital tissue facilities and clinical trial expertise that would be required.
Almost two decades down the road, the next step, they say, requires putting in place a national plan for developing a cell and gene therapy industry across the island similar to what has been achieved for medical devices and other high areas dependent on advanced technology, like ICT and pharmaceuticals. The UK offers a model of what can be achieved as it benefits from a decision by government to heavily invest in gene and cell therapy 15 years ago through an independent body it established called the Cell and Gene Therapy Catapult.
The opportunity for gene and cell therapy to grow here in coming years helped attract Dr Meadhbh Brennan, a post-doctoral researcher at Harvard University, back to Ireland. She also worked at the National Institute of Health and Inserm in France before returning to NUIG to set up her own research group.
In France, Brennan had worked on a clinical trial using stem cells to treat bone defects, while in the US her research focused on factors secreted by stem cells which could be used as a therapeutic. While in the US, she was awarded funding from SFI and that provided impetus for her move home, to take up a position at NUIG working at the interface between engineering and medicine.
She has a European Research Council starting grant award to investigate ways of regenerating bone defects, building on her work in this area. There are more than one million bone grafting procedures performed annually in Europe, and after blood, bone is the most transplanted tissue. There are issues with these procedures, however, as bone tissue is limited in quantity and quality and there is often pain at the surgical site for patients.
Brennan and her team are seeking alternatives to bone grafting through the use of byproducts from the manufacturing of stem cells called extracellular vesicles (EVs). These EVs are tiny biological packages that each contain a therapeutic cargo that has been shown to be capable of enhancing healing processes in tissues by delivering healing messages from cell to cell.
Up to now, EVs have been disposed of as waste products from commercial stem cell manufacturing. We want to divert these discarded products and harness their therapeutic potential, Brennan says, This will make the whole stem cell manufacturing process more efficient and sustainable.
Remedi scientists have experience running patient cell therapy trials, with a trial to treat arthritis of the knee using patients own cells having finished and its results set to be reported during 2022. We dont have the formal results yet, but every piece of information that weve seen about this kind of effort suggests that there is a positive benefit associated with delivering cells to these arthritic joints, Barry says. The next step would be to conduct a larger, well controlled, multinational trial of the therapy, which could be led in Ireland.
There is a huge need for new therapies to treat bone defects, given that about 10 per cent of all bone fractures wont heal if left alone, while bone infection and surgery can leave big voids in bone that need to be healed. This is where new approaches based on EVs can come in, says Brennan. These tiny particles hold huge promise for regenerating not only bone tissue, but also older tissues and organs, and have healing potential in other diseases too.
A key challenge to sort out with EV-based therapies is to find a way to safely transport them from the stem cell manufacturing facility to the clinic. Brennan and her team are investigating ways to allow the vesicles to be stored for longer durations at room temperature. The ultimate goal is to develop novel EV treatments that are inexpensive and available off the shelf when a patient has an injured or damaged tissue or needs an anti-inflammatory treatment.
The whole idea about these technologies is that they are regenerative, stimulate repair or correct defects which are chronic, Barry notes. If they work then you are saving years and years of care associated with chronic illness. The economics of this make an awful lot of sense, and the investment that is needed is very much worth it in terms of the long term.
This is a huge new industry which is exploding worldwide and will require advanced manufacturing capacity in all corners of the world, Barry points out. There is an opportunity for Ireland to become a major centre of this, and we have the people, expertise, and infrastructure to allow the industry to develop here. We need to move with lightning speed to capture the opportunity.
The idea of Ireland becoming a global hub for cell and gene therapy and manufacturing is something we should talk about seriously, he adds.
See the original post:
Tackling chronic disease with gene and cell therapies - The Irish Times
- Kyle Orwig received the Distinguished Researcher Award from the American Society for Reproductive Medicine - University of Pittsburgh - October 4th, 2022
- I Have Cancer And I'm Thankful For The Life Science Industry - Clinical Leader - July 19th, 2022
- Whitmer to veto adoption, abortion alternative funds from Michigan budget - Bridge Michigan - July 19th, 2022
- Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D - Yahoo... - July 11th, 2022
- Amendment added to PA budget bill would make Pitt, other universities stop fetal tissue research - WPXI Pittsburgh - July 3rd, 2022
- Free Fecal Water Syndrome in Horses and What To Do About It The Horse - TheHorse.com - July 3rd, 2022
- PAWcast: Valedictorian Natalia Orlovsky '22 on Research, Mental Health, and Pandemic Princeton - Princeton Alumni Weekly - July 3rd, 2022
- Opinion | Pro-Life Representatives may be the reason thousands of students cant afford Pitt - The Pitt News - June 22nd, 2022
- How one inflammatory disorder exacerbates another | Penn Today - Penn Today - May 2nd, 2022
- ChristianaCare and The Wistar Institute Advance Partnership With New Cancer Research Strategies - ChristianaCare News - March 25th, 2022
- The Incredible Story of Emily Whitehead & CAR T-Cell Therapy : Oncology Times - LWW Journals - March 25th, 2022
- Penn State recipients of Whitaker Center's Women of Impact 2021 awards unite through research - The Daily Collegian Online - March 25th, 2022
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Stockhouse - October 28th, 2021
- NIH, FDA and 15 private organizations join forces to increase effective gene therapies for rare diseases - National Institutes of Health - October 28th, 2021
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases - FDA.gov - October 28th, 2021
- People and places at Penn | Penn Today - Penn Today - Penn Today - August 18th, 2021
- Millions in federal money flowed to tissue bank that collected fetal 'heart, gonads, legs, brain': report - Fox News - August 5th, 2021
- Bispecific Antibodies Wage a Two-Pronged Attack on Tumors - Curetoday.com - June 23rd, 2021
- Newly Discovered Glycosylated RNA Is All Over Cells: Study - The Scientist - May 25th, 2021
- Penn researchers find a way through the labyrinth keeping CAR-T from solid tumors - Endpoints News - December 7th, 2020
- 'Benjamin Button' discovery could reverse ageing process - Queensland Times - December 7th, 2020
- The story of mRNA: From a loose idea to a tool that may help curb Covid - STAT - November 11th, 2020
- Dr. Andreas Sauerbrey: The right orthopaedic diagnosis is essential to proper care - Sky Hi News - September 12th, 2020
- T cells, B cells and the range of the human bodys immune response A simple decoder - ThePrint - August 10th, 2020
- Are very long-lived trees immortal and what can they teach humans? - ABC News - August 10th, 2020
- Eradicating balding a step closer with new procedure in the cross hairs - The New Daily - June 4th, 2020
- Coming Together to Solve COVID-19 Mysteries | University of Pennsylvania Almanac - UPENN Almanac - June 4th, 2020
- Orthopedics - Pennsylvania Stem Cell Center - May 25th, 2020
- Stem Cell Treatment Bala Cynwyd | Stem Cell Therapy ... - May 25th, 2020
- Vasomune Therapeutics Announces Clinical and Scientific Advisory Board - BioSpace - May 11th, 2020
- Chinas scientists accused of playing God by creating monstrous cloned apes and primates with human organs - The Sun - May 11th, 2020
- Pregnant and positive | Scientists look for COVID-19 immunity in the womb - WHAS11.com - April 23rd, 2020
- Why Choose Us - Pennsylvania Stem Cell Center - April 10th, 2020
- Moderna: A $12 Billion Brand Built On Hope And mRNA - Seeking Alpha - April 10th, 2020
- The potential use of CRISPR to treat disease is gaining momentum - BioNews - January 16th, 2020
- What a time to be alive: Reproductive breakthroughs of the 2010s that changed life as we know it - FOX 10 News Phoenix - January 3rd, 2020
- 2019: The year gene therapy came of age - Jamaica Observer - December 9th, 2019
- Trevena Inc. (TRVN)'s Financial Results Comparing With VistaGen Therapeutics Inc. (NASDAQ:VTGN) - The Broch Herald - December 9th, 2019
- 253 miles in 4 hours: A Syracuse mans race for a lung transplant, and the angel who helped him - syracuse.com - December 1st, 2019
- Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) & Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger - December 1st, 2019
- Critical Review: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - NCTY News - November 16th, 2019
- These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News - NoCamels - Israeli Innovation News - November 16th, 2019
- Reviewing BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger - November 16th, 2019
- Reviewing Madrigal Pharmaceuticals Inc. (MDGL)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 30th, 2019
- Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy - Seeking Alpha - October 30th, 2019
- AI uncovers genes linked to heart failure - FierceBiotech - September 27th, 2019
- University of Pennsylvania || Cell and Molecular Biology ... - September 7th, 2019
- Robert Lanza - Wikipedia - May 12th, 2019
- Cary Ortho Utilizes Bone Marrow Stem Cells for General ... - May 12th, 2019
- Stem Cell Therapy in Lancaster Pennsylvania | Stem Cell ... - April 24th, 2019
- Lung Institute Review | Do Stem Cell Treatments Work? - April 21st, 2019
- Cells Weekly October 11, 2015 - stemcellassays.com - February 5th, 2019
- Pittsburgh, Pennsylvania - Stem Cells Transplant Institute - November 18th, 2018
- Stem Cell Therapy in York County, Pennsylvania - October 8th, 2018
- Regrowing dental tissue with stem cells from baby teeth ... - October 2nd, 2018
- About Penn's IRM - Institute for Regenerative Medicine - September 16th, 2018
- Stem Cell Treatment - Philadelphia Bala Cynwyd, PA: World ... - August 13th, 2018
- Stem Cell Therapy in Conewago Township, Pennsylvania - July 19th, 2018
- Meetings - October 8th, 2017
- Tucson's Calimmune to be acquired by Australian drug giant - Arizona Daily Star - August 30th, 2017
- Hair Regrowth using Stem Cells | Ashley and Martin - August 30th, 2017
- Bone Marrow Protein May Be Target for Improving Stem Cell Transplants - Penn: Office of University Communications - August 30th, 2017
- Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young ... - GlobeNewswire (press release) - August 30th, 2017
- COLUMN: Startling statistics concerning drug deaths in rural communities - Meadville Tribune - August 25th, 2017
- Rare leukemia targeted by modifying patients' immune cells - New Haven Register - August 7th, 2017
- Campus achievement - Sunbury Daily Item - August 7th, 2017
- La Jolla Light News Nuggets: July 27 - La Jolla Light - July 30th, 2017
- 2016 Scientific Program - December 4th, 2016
- Tissue Niches & Resident Stem Cells in Adult Epithelia - GRC - August 26th, 2016
- Knee Stem Cell Therapy and Platelet Procedures Pittsburgh ... - July 2nd, 2015
- Penn vet team points to new colon cancer culprit - March 16th, 2015
- MD Anderson Names Hwu as Head of Cancer Medicine - February 26th, 2015
- Stemiotics Licenses Modified RNA for Cell Reprogramming - December 22nd, 2014
- Penn Medicine Researchers Announce Latest Results of Investigational Cellular Therapy CTL019 - December 8th, 2014
- Cyanide killed hospital employee, official says - November 29th, 2014
- An Eclectic Path to Precision Medicine - November 25th, 2014
- First Study to Convert Adult Human Cells to Hair-Follicle ... - November 2nd, 2014
- Stem Cell and Xenograft Core: Biomedical Research Core ... - October 27th, 2014
- Immune Therapy Induces Remission for Many With a Tough-to-Treat Blood Cancer - October 18th, 2014
- Sangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014 - October 16th, 2014